Cite
Koretz RL, Jakobsen JC, Gluud C. Letter to the editor re: Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment. BMJ Evid Based Med. 2018;23(6):240doi: 10.1136/bmjebm-2018-111072.
Koretz, R. L., Jakobsen, J. C., & Gluud, C. (2018). Letter to the editor re: Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment. BMJ evidence-based medicine, 23(6), 240. https://doi.org/10.1136/bmjebm-2018-111072
Koretz, Ronald L, et al. "Letter to the editor re: Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment." BMJ evidence-based medicine vol. 23,6 (2018): 240. doi: https://doi.org/10.1136/bmjebm-2018-111072
Koretz RL, Jakobsen JC, Gluud C. Letter to the editor re: Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment. BMJ Evid Based Med. 2018 Dec;23(6):240. doi: 10.1136/bmjebm-2018-111072. Epub 2018 Aug 31. PMID: 30171020.
Copy
Download .nbib
